Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 03 Nov 2021
Government makes a mockery of PHARMAC review
3 November 2021 - “The ACT Party can today reveal the review into PHARMAC has been delayed by more than ...
Posted by Michael Wonder on 03 Nov 2021
President Biden announces prescription drug pricing plan in build back better framework
2 November 2021 - Nearly 1 in 4 Americans struggle to afford prescription drugs. ...
Posted by Michael Wonder on 03 Nov 2021
Major PHARMAC review delayed nearly 3 months
3 November 2021 - A major review into Government drug buying agency PHARMAC has been delayed by nearly three months. ...
Posted by Michael Wonder on 03 Nov 2021
Democrats revive drug pricing reform with a narrow set of proposed measures
2 November 2021 - On Tuesday 2 November, Senator Schumer announced that an agreement had been reached regarding lowering drug ...
Posted by Michael Wonder on 03 Nov 2021
Opdivo receives two new Health Canada approvals
2 November 2021 - Today Bristol Myers Squibb Canada announces two recent Health Canada approvals for Opdivo (nivolumab). ...
Posted by Michael Wonder on 03 Nov 2021
Health Canada issues Notice of Compliance for Jardiance (empagliflozin) for the treatment of heart failure with reduced ejection fraction
2 November 2021 - This new indication is based on the EMPEROR-Reduced trial, which showed a significant 25% reduction in the ...
Posted by Michael Wonder on 03 Nov 2021
Amylyx Pharmaceuticals submits new drug application for AMX0035 for the treatment of ALS
2 November 2021 - Amylyx Pharmaceuticals today announced it has submitted a new drug application to the U.S. FDA for AMX0035 ...
Posted by Michael Wonder on 03 Nov 2021
Department of Health tweaks agenda for this week's PBAC meeting
1 November 2021 - This is the tenth revision to the agenda for this week's PBAC meeting. ...
Posted by Michael Wonder on 02 Nov 2021
FDA grants breakthrough status for Alzheimer's treatment
2 November 2021 - Renew Bioscience announced it has received breakthrough device designation status from the U.S. FDA for the ...
Posted by Michael Wonder on 02 Nov 2021
Pricing vaccines and drugs in Europe: worth differentiating?
1 November 2021 - The COVID-19 pandemic has recently brought to the forefront the vital importance of vaccines, of which Europe ...
Posted by Michael Wonder on 02 Nov 2021
I’ve worked with Robert Califf. He is the leader the FDA needs.
2 November 2021 - If the cascade of news reports are true, President Biden is finally about to name his choice ...
Posted by Michael Wonder on 02 Nov 2021
Democrats reach a breakthrough deal on drug prices, as spending bill nears the finish line
2 November 2021 - Senate Majority Leader Chuck Schumer said Tuesday that Democrats reached an agreement on lowering prescription drug prices. ...
Posted by Michael Wonder on 02 Nov 2021
Delaware to regulate multi-billion dollar pharmacy benefit manager industry, protecting consumers and local businesses
2 November 2021 - Department of Insurance will lead effort to rein in monopolistic behaviour and excessive pharmaceutical costs. ...
Posted by Michael Wonder on 02 Nov 2021
EMA ends rolling review of the antibodies bamlanivimab and etesevimab for COVID-19 following withdrawal by Lilly
2 November 2021 - EMA has ended the rolling review of bamlanivimab and etesevimab, two antibodies for the treatment of ...
Posted by Michael Wonder on 02 Nov 2021
Otsuka submits initial marketing authorization application to the European Medicines Agency for vadadustat for the treatment of adults with anemia associated with chronic kidney disease
29 October 2021 - Otsuka announces that Otsuka Pharmaceutical Netherlands has submitted an initial marketing authorisation application to the EMA for ...